Crescent Biopharma, Inc.
CBIO
$13.41
$0.322.45%
NASDAQ
| 09/30/2025 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | -38.12% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 23.09% | ||||
| Operating Income | -23.09% | ||||
| Income Before Tax | -12.93% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -12.93% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -12.93% | ||||
| EBIT | -23.09% | ||||
| EBITDA | -22.96% | ||||
| EPS Basic | 74.30% | ||||
| Normalized Basic EPS | 74.30% | ||||
| EPS Diluted | 74.30% | ||||
| Normalized Diluted EPS | 74.30% | ||||
| Average Basic Shares Outstanding | 339.37% | ||||
| Average Diluted Shares Outstanding | 339.37% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||